The objectives of the UCLA SPORE in Brain Cancer are to contribute significantly to progress in the diagnosis, prognosis, and treatment of brain cancer. These goals will be accomplished through multiple and diverse research projects involving mechanistic pre-clinical work and innovative clinical studies, with a particular focus on developing novel strategies to overcome the problem of treatment resistance. The broad, long-term objectives and aims of our brain cancer SPORE are as follows: 1) to investigate mechanisms of immune evasion following active immunotherapy, and develop rational combinations of immunotherapeutic strategies to overcome the immunosuppressive milieu of the brain tumor microenvironment; 2) to elucidate the alterations in metabolism associated with targeted therapy resistance, and exploit these metabolic vulnerabilities to induce intrinsic apoptosis of tumor cells; 3) to explore the concept of radiation-induced phenotype conversion of non-tumorigenic cells to glioblastoma-initiating cells as a mechanism for radiation resistance, and test new therapeutics to block such glioma stem cell conversion; and 4) to investigate the pathways of resistance to IDH inhibitors, and utilize novel epigenetic pathways to sensitize IDH-mutant gliomas to treatment. In order to achieve these translational research goals of our program, we propose four main projects involving: 1) active immunotherapy combined with immune checkpoint modulation for glioblastoma; 2) targeting metabolic vulnerabilities in glioblastoma cells; 3) inhibition of radiation-induced phenotype conversion to glioma-initiating stem cells; and 4) novel epigenetic treatment of IDH mutant gliomas. These translational research projects will be supported by shared resource cores in administration, biospecimen/pathology, neuroimaging, and biostatistics/bioinformatics/data management. Our program will also be responsive to SPORE themes by incorporating Developmental Research and Career Enhancement Programs in order to foster new approaches for assessing and treating brain cancer. Our diverse array of novel projects and state-of-the-art cores will likely make a significant impact on brain cancer patient care. Each project has been developed jointly by teams of basic and clinical researchers working together in a trans-disciplinary manner to address the most vexing problem in brain cancer ? the development of treatment resistance. All four projects are highly translational and will reach human endpoints within the context of this SPORE grant period.

Public Health Relevance

Overall: UCLA SPORE in Brain Cancer NARRATIVE The UCLA Brain Cancer SPORE will support research into new and innovative strategies to diagnose and treat brain cancer, particularly focusing on novel ways to overcome the problem of treatment resistance. Despite many different treatment approaches, the five-year survival rate for glioblastoma (WHO grade IV glioma) patients is still <5%, and there are no definitive cures for this disease. Thus, the proposed research is of relevance to public health, as there is clearly an unmet need for patients with this type of cancer and novel therapeutic approaches are warranted.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Arnold, Julia T
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Los Angeles
Schools of Medicine
Los Angeles
United States
Zip Code
Chakhoyan, Ararat; Woodworth, Davis C; Harris, Robert J et al. (2018) Mono-exponential, diffusion kurtosis and stretched exponential diffusion MR imaging response to chemoradiation in newly diagnosed glioblastoma. J Neurooncol 139:651-659
Mehta, Shwetal (2018) Editorial: The Role of Microenvironment in the Homing, Maintenance, and Release of Glioma Stem-Like Cells. Front Oncol 8:7
Orozco, Luz D; Farrell, Colin; Hale, Christopher et al. (2018) Epigenome-wide association in adipose tissue from the METSIM cohort. Hum Mol Genet 27:1830-1846
Garrett, Matthew; Sperry, Jantzen; Braas, Daniel et al. (2018) Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities. Cancer Metab 6:4
Yu, Songlin; Ma, Samantha J; Liebeskind, David S et al. (2018) ASPECTS-based reperfusion status on arterial spin labeling is associated with clinical outcome in acute ischemic stroke patients. J Cereb Blood Flow Metab 38:382-392
Keegan, Caroline; Krutzik, Stephan; Schenk, Mirjam et al. (2018) Mycobacterium tuberculosis Transfer RNA Induces IL-12p70 via Synergistic Activation of Pattern Recognition Receptors within a Cell Network. J Immunol 200:3244-3258
Gupta, Arpana; Woodworth, Davis C; Ellingson, Benjamin M et al. (2018) Disease-Related Microstructural Differences in the Brain in Women With Provoked Vestibulodynia. J Pain 19:528.e1-528.e15
L├╝ckerath, Katharina; Stuparu, Andreea D; Wei, Liu et al. (2018) Detection Threshold and Reproducibility of 68Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer. J Nucl Med 59:1392-1397
Li, Tie; Cox, Christopher D; Ozer, Byram H et al. (2018) D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant-Induced MIR148A Promoter Methylation. Mol Cancer Res 16:947-960
Pope, Whitney B (2018) Brain metastases: neuroimaging. Handb Clin Neurol 149:89-112

Showing the most recent 10 out of 91 publications